Consensus on diagnosis and management of Cushing's disease: a guideline update

M Fleseriu, R Auchus, I Bancos… - The lancet Diabetes & …, 2021 - thelancet.com
Cushing's disease requires accurate diagnosis, careful treatment selection, and long-term
management to optimise patient outcomes. The Pituitary Society convened a consensus …

Complications of Cushing's syndrome: state of the art

R Pivonello, AM Isidori, MC De Martino… - The lancet Diabetes & …, 2016 - thelancet.com
Cushing's syndrome is a serious endocrine disease caused by chronic, autonomous, and
excessive secretion of cortisol. The syndrome is associated with increased mortality and …

Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase

R Pivonello, M Fleseriu, J Newell-Price… - The Lancet Diabetes & …, 2020 - thelancet.com
Background Cushing's disease is a rare endocrine disorder characterised by cortisol
overproduction with severe complications. Therapies for cortisol reduction are often …

The treatment of Cushing's disease

R Pivonello, M De Leo, A Cozzolino… - Endocrine …, 2015 - academic.oup.com
Abstract Cushing's disease (CD), or pituitary-dependent Cushing's syndrome, is a severe
endocrine disease caused by a corticotroph pituitary tumor and associated with increased …

Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification

ASG Micko, A Wöhrer, S Wolfsberger, E Knosp - Journal of neurosurgery, 2015 - thejns.org
OBJECT An important prognostic factor for the surgical outcome and recurrence of a pituitary
adenoma is its invasiveness into parasellar tissue, particularly into the space of the …

Cushing's syndrome

A Lacroix, RA Feelders, CA Stratakis, LK Nieman - The lancet, 2015 - thelancet.com
Chronic exposure to excess glucorticoids results in diverse manifestations of Cushing's
syndrome, including debilitating morbidities and increased mortality. Genetic and molecular …

International Union of Basic and Clinical Pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature

T Günther, G Tulipano, P Dournaud, C Bousquet… - Pharmacological …, 2018 - Elsevier
Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that
exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its …

Recurrent gain-of-function USP8 mutations in Cushing's disease

ZY Ma, ZJ Song, JH Chen, YF Wang, SQ Li, LF Zhou… - Cell research, 2015 - nature.com
Cushing's disease, also known as adrenocorticotropic hormone (ACTH)-secreting pituitary
adenomas (PAs) that cause excess cortisol production, accounts for up to 85% of …

[HTML][HTML] A 12-month phase 3 study of pasireotide in Cushing's disease

A Colao, S Petersenn, J Newell-Price… - … England Journal of …, 2012 - Mass Medical Soc
Background Cushing's disease is associated with high morbidity and mortality. Pasireotide,
a potential therapy, has a unique, broad somatostatin-receptor–binding profile, with high …

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome

M Fleseriu, BMK Biller, JW Findling… - The Journal of …, 2012 - academic.oup.com
Context: Cushing's syndrome (CS) is a disorder associated with significant morbidity and
mortality due to prolonged exposure to high cortisol concentrations. Objective: Our objective …